The management of the RusnanoMedInvest Venture Fund has been outsourced to a company called RMI Partners, based on an agreement with RUSNANO.
RMI Partners is a global life sciences venture capital investment firm. It's investment strategy is a technology-, therapeutic-area-, clinical-context- and geography-agnostic. RMI Partners invests in exceptional early- to mid-stage life sciences opportunities with a potential to deliver genuinely step-change productivity, efficiency and effectiveness impact to the key healthcare stakeholders simultaneously, including patients, payers, caregivers, healthcare professionals and regulators.
More information www.rmivc.com
Pfizer Inc, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio. The deal will enable Pfizer and NovaMedica to improve the health of patients in Russia and modernize the Russian pharmaceutical industry.
26 April 2017
25 April 2017